For instance, agonists targeting CLRs are being explored as potential vaccine adjuvants, as they can enhance immune responses to viral infections.[75] In contrast, modulation of RLR and ALR signaling holds promise for treating cytokine storms in viral infections and other autoimmune diseases. The gene discussed is LARS1; the disease is viral infectious disease.